ENALAPRILAT INJECTION USP SOLUTION

Land: Canada

Taal: Engels

Bron: Health Canada

Werkstoffen:

ENALAPRILAT

Beschikbaar vanaf:

HIKMA CANADA LIMITED

ATC-code:

C09AA02

INN (Algemene Internationale Benaming):

ENALAPRIL

Dosering:

1.25MG

farmaceutische vorm:

SOLUTION

Samenstelling:

ENALAPRILAT 1.25MG

Toedieningsweg:

INTRAVENOUS

Eenheden in pakket:

15G/50G

Prescription-type:

Prescription

Therapeutisch gebied:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Product samenvatting:

Active ingredient group (AIG) number: 0118001001; AHFS:

Autorisatie-status:

APPROVED

Autorisatie datum:

2023-07-10

Productkenmerken

_ _
_Enalaprilat Injection USP - Product Monograph _
_Page 1 of 28_
PRODUCT MONOGRAPH
PR
ENALAPRILAT INJECTION USP
Solution for Injection, 1.25 mg/mL
Angiotensin Converting Enzyme Inhibitor
Hikma Canada Limited
5995 Avebury Road, Suite 804
Mississauga, ON L5R 3P9
Date of Preparation:
JUL 10, 2023
Control Number: 276100
_ _
_Enalaprilat Injection USP - Product Monograph _
_Page 2 of 28_
TABLE OF CONTENTS
PART 1: HEALTH PROFESSIONAL
INFORMATION………………………………
3
SUMMARY PRODUCT
INFORMATION………………………………………………
3
INDICATIONS AND CLINICAL
USE…………………………………………………..
3
CONTRAINDICATIONS…………………………………………………………………
3
WARNINGS AND
PRECAUTIONS……………………………………………………..
4
ADVERSE
REACTIONS…………………………………………………………………
7
DRUG
INTERACTIONS…………………………………………………………………
11
DOSAGE AND
ADMINISTRATION……………………………………………………
12
OVERDOSAGE…………………………………………………………………………...
14
ACTION AND CLINICAL
PHARMACOLOGY………………………………………..
14
STORAGE AND
STABILITY……………………………………………………………
15
DOSAGE FORMS, COMPOSITION AND
PACKAGING……………………………...
15
PART II: SCIENTIFIC
INFORMATION…………………………………………………
16
PHARMACEUTICAL
INFORMATION…………………………………………………
16
DETAILED
PHARMACOLOGY………………………………………………………...
16
TOXICOLOGY……………………………………………………………………………
18
REFERENCES…………………………………………………………………………….
23
PART III: CONSUMER
INFORMATION………………………………………………...
25
_ _